Immunoglobulin G Therapy Dose Optimization
Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · Mar 23, 2021
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how obesity affects the way the body processes a treatment called immunoglobulin G (IgG), which is often given to help patients with immune deficiencies. The researchers aim to find better ways to determine the right dose of IgG for individuals who are obese, as current dosing strategies may not be suitable and could lead to side effects. The trial is open to adults aged 18 to 75 who are currently receiving IgG treatment through an intravenous (IV) method.
To participate, individuals must not have serious liver or kidney problems and should not have certain heart devices like a pacemaker. Those who join the study can expect to undergo assessments that help the researchers understand how their body responds to the treatment. This research is important because it aims to improve the safety and effectiveness of IgG therapy for obese patients, addressing a significant gap in current medical knowledge.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • aged 18 to 75 years
- • currently treated with IVIG
- Exclusion Criteria:
- • liver impairment (elevations in liver enzymes of greater than 3 times the upper limit of normal)
- • reduced renal function (CrCl \< 50 mL/min)
- • Patients with a pacemaker or an automatic implantable cardioverter-defibrillator
About Rutgers, The State University Of New Jersey
Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Somerville, New Jersey, United States
Patients applied
Trial Officials
Luigi Brunetti, Ph D; PharmD
Principal Investigator
Rutgers University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials